Project Details
| Short title | NN9388-4896 |
|---|---|
| Acronym | REIMAGINE 2 |
| Status | Active |
| Effective start/end date | 12/11/23 → 25/10/28 |
CTU: Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
- Preda, Veronica (Primary Chief Investigator)
- Contacos, Christine (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
Project: Research